

Roberto Nitsch graduated in Medical Biotechnology from the University of Naples (Italy) where he also obtained his PhD in Molecular Genetics. He later moved to Vienna where he focused on mouse genetics and cancer biology, and lately recessive genetics. He then shifted his research topic to genome engineering with CRISPR/Cas9 and joined AstraZeneca in 2014 where he was responsible of the CRISPR mouse models for drug discovery and oncology. Since 2017, he is Associate Director in the Clinical Pharmacology and Safety Sciences pioneering safety assessments for Therapeutic Genome Editing. Today Roberto is the Director of the Gene Therapy safety group at AstraZeneca, and he is supporting the generation of CRISPR medicines.